A REVIEW OF TRULICITY 1.5 MG

The trial realized both of those its Key endpoints, with semaglutide 2.four mg demonstrating statistically substantial and remarkable improvements in liver fibrosis without worsening of steatohepatitis, in addition to resolution of steatohepatitis without any worsening of liver fibrosis in people with MASH compared to placebo.1Assuming the above as